Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 78 recruiting now early-phase tilt #65 of 28,707 conditions

Epilepsy: early-phase trial registry

78 of 164 indexed Epilepsy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #65 of 28,707 conditions by registered trial count.

164 US clinical trials · 78 currently recruiting · #65 of 28,707 conditions by registered trial count

Epilepsy: 164 US clinical trials tracked, 78 recruiting.

Epilepsy is the subject of 164 registered US clinical trials on ClinicalTrials.gov, 78 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 39 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Neurological Disorders and Stroke (NINDS), running 9 of these trials.

Enrollment posture brief

Registry condition epilepsy

OPEN 78 | RECR 48% | LATE 21 | EARLY 39 | RANK #65 | SPON 9

Nearest open-share peer: Microbial Colonization (48% recruiting · 21 trials)

Epilepsy (this)48%Gastric Cancer45.3%Neoplasms31.3%Parkinson's Disease26.1%Bipolar Disorder22.7%
Open-enrollment share among volume-matched conditions near Epilepsy

Epilepsy lists 78 open slots (48% of 164 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Epilepsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Epilepsy is recruiting above its size-band peers.

    78 of 164 indexed trials (47.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Epilepsy trials is spread across many organizations.

    National Institute of Neurological Disorders and Stroke (NINDS) accounts for 9 of 164 trials (5.5%). 95 distinct sponsors appear on at least one study for this condition label.

  3. Most Epilepsy trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 161 trials that report a genuine target (sentinel values excluded). 103 of those (64%) plan for fewer than 100 participants.

  4. Epilepsy research is mostly interventional.

    120 interventional and 44 observational studies make up this index (73.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 123Phase 216Phase 314Phase 47

Open and recent trials

164 total, page 3 of 4

COMPLETED 199 participants

Women With Epilepsy: Pregnancy Outcomes and Deliveries

NYU Langone Health

NCT01259310

COMPLETED Phase 2 197 participants

Pediatric Epilepsy Study in Subjects 1-24 Months

GlaxoSmithKline

NCT00044278

COMPLETED Phase 3 190 participants

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

UCB Pharma

NCT00419393

COMPLETED 185 participants

Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study

Icahn School of Medicine at Mount Sinai

NCT00041951

COMPLETED Phase 3 171 participants

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Jazz Pharmaceuticals

NCT02224690

COMPLETED Phase 2 150 participants

Study of an External Responsive Neurostimulator System on Epileptiform Activity

NeuroPace

NCT00158067

COMPLETED Phase 3 132 participants

Pediatric Epilepsy Study

Novartis Pharmaceuticals

NCT00050934

COMPLETED NA 130 participants

Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT

Emory University

NCT01941706

COMPLETED Phase 2 125 participants

Hormone Replacement in Menopausal Women With Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00027209

COMPLETED NA 122 participants

High-density EEG in Neurological Disorders

Dartmouth-Hitchcock Medical Center

NCT04266041

COMPLETED NA 121 participants

Self-management for People With Epilepsy and a History of Negative Health Events

Case Western Reserve University

NCT02970396

COMPLETED NA 120 participants

Youth Epilepsy and Successful Self-Management Intervention

University of Minnesota

NCT03639233

COMPLETED NA 104 participants

Behavioral Economics and Adherence in Teens (BEAT!)

Children's Hospital Medical Center, Cincinnati

NCT03958331

COMPLETED 102 participants

Bipolar Disorder in Epilepsy

Northwell Health

NCT00365482

COMPLETED Phase 2 100 participants

Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

UCB Pharma

NCT00422422

COMPLETED 97 participants

A Complex Contraception Registry

University of California, San Diego

NCT02219269

COMPLETED Phase 3 94 participants

Pediatric Epilepsy Study

Novartis Pharmaceuticals

NCT00050947

COMPLETED Phase 1 88 participants

COPE Intervention for Parents of Children With Epilepsy

Boston Children's Hospital

NCT00767026

COMPLETED NA 82 participants

Adapting Project UPLIFT for Blacks in Georgia

Morehouse School of Medicine

NCT02909387

COMPLETED 81 participants

Study of Antiepileptic Drug Effects on Child Development

Augusta University

NCT00353886

COMPLETED NA 80 participants

Utilizing Activity Trackers to Promote Physical Activity in People With Epilepsy: Can we Make a Difference?

The University of Texas Health Science Center, Houston

NCT04357912

COMPLETED Phase 1 67 participants

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Bial - Portela C S.A.

NCT02283788

COMPLETED NA 50 participants

A Computerized CBTi for Insomnia in Epilepsy

The Cleveland Clinic

NCT03632889

COMPLETED NA 48 participants

Flexible Representation of Speech

University of Pittsburgh

NCT05209386

COMPLETED Phase 2 45 participants

Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures

Jazz Pharmaceuticals

NCT00594945

COMPLETED NA 42 participants

Counseling on the Interaction of Hormonal Contraceptives and Antiepileptics

University of California, San Diego

NCT02485756

COMPLETED 40 participants

Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

Beth Israel Deaconess Medical Center

NCT03103425

COMPLETED Phase 3 40 participants

IV Lacosamide: The Safety of Intravenous Lacosamide

Le Bonheur Children's Hospital

NCT01981447

COMPLETED Phase 1 40 participants

TAK-935 Multiple Rising Dose Study in Healthy Participants

Takeda

NCT02539134

COMPLETED Phase 2 39 participants

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

UCB Biosciences

NCT01118962

COMPLETED 38 participants

Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?

Northwell Health

NCT01231646

COMPLETED 38 participants

Study of [11C]DPA-713 for Temporal Lobe Epilepsy

National Institute of Mental Health (NIMH)

NCT01793532

COMPLETED 35 participants

Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00071305

COMPLETED NA 31 participants

Cognitive Effects of Treatment of Interictal Discharges

Massachusetts General Hospital

NCT00916149

COMPLETED Phase 1 31 participants

Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study

Aquestive Therapeutics

NCT03953820

COMPLETED Phase 2 30 participants

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

Rup Kamal Sainju

NCT02929667

COMPLETED NA 30 participants

Use of the Atkins Diet for Adults With Intractable Epilepsy

Johns Hopkins University

NCT00121927

COMPLETED Phase 2 30 participants

Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies

Marinus Pharmaceuticals

NCT02358538

COMPLETED Phase 1 30 participants

An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

GlaxoSmithKline

NCT01583036

COMPLETED NA 30 participants

Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS

NYU Langone Health

NCT02263274

COMPLETED NA 29 participants

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

American Academy of Neurology

NCT01054599

COMPLETED Phase 1 24 participants

A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers

University of Minnesota

NCT01364558

COMPLETED Phase 2 24 participants

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

National Center for Complementary and Integrative Health (NCCIH)

NCT00871377

COMPLETED Phase 4 24 participants

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

Drexel University College of Medicine

NCT01318408

COMPLETED Phase 2 24 participants

Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy

Aquestive Therapeutics

NCT03222349

COMPLETED Phase 4 20 participants

Epidiolex® for Anxiety in Pediatric Epilepsy

Hugo W. Moser Research Institute at Kennedy Krieger

NCT05324449

COMPLETED NA 20 participants

VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)

Cyberonics

NCT01846741

COMPLETED 20 participants

Language and Emotional Function in Patients With Temporal Lobe Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00081432

COMPLETED Phase 4 20 participants

Fycompa Titration Intervals and Effects on Retention Rate

University of Arizona

NCT03457129

COMPLETED 19 participants

Epilepsy Motion Sensing

MedtronicNeuro

NCT01850498

← Previous Page 3 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 23
Phase 2 16
Phase 3 14
Phase 4 7

Named interventions

Most-linked intervention names on Epilepsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
14 trials
Project UPLIFT Behavioral
3 trials
Brivaracetam Drug
3 trials
Levetiracetam Drug
3 trials
Lamotrigine Drug
3 trials
Diazepam Buccal Film Drug
2 trials
oxcarbazepine Drug
2 trials
Individualized Adherence Feedback Report Behavioral
2 trials

US sites by state

Facility locations filed on Epilepsy trials. A trial with sites in several states counts in each.

New York 38 trials
Massachusetts 35 trials
California 31 trials
Florida 30 trials
Minnesota 29 trials
Texas 28 trials
Ohio 26 trials
Maryland 26 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Epilepsy page

164 registered trials, 78 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epilepsy condition card totals 164 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.